Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis

NCT01262001 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT01262001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis
Lead sponsor
Kyntra Bio
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
June 21, 2017
Enrollment
90 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis